Home/Pipeline/UNITED Study (Investigational Inflatable Penile Prosthesis)

UNITED Study (Investigational Inflatable Penile Prosthesis)

Erectile Dysfunction

Clinical InvestigationActive

Key Facts

Indication

Erectile Dysfunction

Phase

Clinical Investigation

Status

Active

Company

Rigicon

About Rigicon

Rigicon is a privately held medical device company specializing in prosthetic urology, with a core focus on erectile dysfunction (ED) treatment. The company's primary commercial product is the Rigi10™, a next-generation malleable penile prosthesis featuring proprietary technologies like HydroShield™ coating and Flexible Rod Technology™. Rigicon operates globally from its headquarters in Ronkonkoma, New York, and positions itself as a scientific partner aiming to change the practice of prosthetic urology through innovation and a complete product portfolio. The company is in a revenue-generating, commercial stage, serving the urology surgical market.

View full company profile

Therapeutic Areas

Urology Erectile Dysfunction

Other Erectile Dysfunction Drugs

Drug	Company	Phase	Status
CF602	Can Fite Biopharma	Preclinical	Active
E300 ESWT System	Wikkon	Commercial	Market Released
Sildenafil Citrate	Azico Biophore	Commercial	Active
Sildenafil Formulation	InnovaZone Labs	Approved	Active
Rigi10™ Malleable Penile Prosthesis	Rigicon	Approved	Commercial
ASP-001	Aspargo Laboratories	Approved	Active
Sildenafil-loaded Z-pods®	Atticus Pharma	Pre-clinical	Active
FGF-based Therapeutic	Venturis Therapeutics	Pre-clinical	Active
TPN171 (Simenafil hydrochloride) Tablets	Vigonvita	Approved	Marketed in China and Uzbekistan
DehydraTECH-sildenafil	Lexaria Bioscience	Human Clinical	Active